Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISRUPT: Ombrabulin in Metastatic NSCLC
NCT01263886Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of Ombrabulin in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Feb 2011; status: completed.
02
Drugs
Ombrabulin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01263886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01263886.